Scolaris Content Display Scolaris Content Display

Vacunación de la hepatitis B durante el embarazo para la prevención de la infección en lactantes

Collapse all Expand all

References

Referencias de los estudios excluidos de esta revisión

Gupta 2003 {published data only}

Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. Journal of Obstetrics and Gynaecology Research 2003;29(2):84‐6.

Li 2003 {published data only}

Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, et al. Interruption of HBV intrauterine transmission: a clinical study. World Journal of Gastroenterology 2003;9(7):1501‐3.

Li 2004 {published data only}

Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World Journal of Gastroenterology 2004;10(21):3215‐7.

Patwardhan 2005 {published data only}

Patwardhan A, Jamjute P, Peter G. Foetal immunoprophylaxis with hepatitis‐B vaccine could be a cost effective approach towards eradication in the high‐risk population. Journal of Pediatric Gastroenterology and Nutrition 2005;40(5):678.

Wang 2008 {published data only}

Wang FY, Lin P, Zhang HZ. [A randomized controlled trial on effect of hepatitis B immune globulin in preventing hepatitis B virus transmission from mothers to infants]. [Chinese]. Zhonghua Erke Zazhi 2008;46(1):61‐3.

Xu 2004 {published data only}

Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li M, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother‐child transmission of hepatitis B; a multicentre, randomised, double‐blind, placebo‐controlled study. Hepatology 2004;40(4 Suppl 1):272A‐273A.

Xu 2006 {published data only}

Xu Q, Xiao L, Lu XB, Zhang YX, Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World Journal of Gastroenterology 2006;12(21):3434‐7.

Xu 2009 {published data only}

Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study. Journal of Viral Hepatitis 2009;16(2):94‐103.

Yu 2003 {published data only}

Yu F, Xin QX, Li DR. Clinical observation of blocking HBV intrauterine infection by injection of hepatitis B immunoglobulin before laboring. Clinical Medicine of China 2003;19(11):1049‐50.

Yuan 2006 {published data only}

Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single‐centre randomized study. Journal of Viral Hepatitis  2006;13(9):597‐604.

Yue 1999 {published data only}

Yue Y, Yang X, Zhang S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism. Chinese Medical Journal 1999;112(1):37‐9.

Zhu 1997 {published data only}

Zhu Q, Lu Q, Gu X, Xu H, Duan S. A preliminary study on interruption of HBV transmission in uterus. Chinese Medical Journal 1997;110:145‐7.

Zhu 2003 {published data only}

Zhu Q, Yu G, Yu H, Lu Q, Gu X, Dong Z, et al. A randomized control trial on interruption of HBV transmission in uterus. Chinese Medical Journal 2003;116(5):685‐7.

Referencias adicionales

Andre 1989

Andre FE. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. American Journal of Medicine 1989;87(Suppl 3A):14S‐20S.

Anonymous 1991

Anonymous. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports1991; Vol. 40, issue RR‐13:1‐25.

Assad 1999

Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999;18(1‐2):57‐67.

Beasley 1975

Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breastfeeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2(7938):740‐1.

Chang 1998

Chang MH. Hepatocellular carcinoma in children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1998;39(6):366‐70.

De Lalla 1988

De Lalla F, Rinaldi E, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. European Journal of Epidemiology 1988;4(2):256‐8.

Ghendon 1987

Ghendon Y. Perinatal transmission of hepatitis B virus in high‐incidence countries. Journal of Virological Methods 1987;17(1‐2):69‐79.

Gitlin 1997

Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clinical Chemistry 1997;43(8 Pt 2):1500‐6.

GRADE 2008

GRADE [Computer program]. Brozek J, Oxman A, Schünemann H. Version 3.6 for Windows2008.

Greenberg 1993

Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunization studies. Pediatric Infectious Disease Journal 1993;12(5):438‐45.

Grosheide 1993

Grosheide PM, Schalm SW, Van Os HC, Fetter WP, Heijtink RA. Immune response to hepatitis B vaccine in pregnant women receiving post‐exposure prophylaxis. European Journal of Obstetrics & Gynecology and Reproductive Biology 1993;50(1):53‐8.

Higgins 2011

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Hollinger 2001

Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA editor(s). Fields Virology. 4th Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2971‐3036.

Hsieh 1992

Hsieh CC, Tzonou A, Zavitsanos X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. American Journal of Epidemiology 1992;136(9):1115‐21.

Ingardia 1999

Ingardia CJ, Kelley L, Steinfeld JD, Wax JR. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstetrics & Gynecology 1999;93(6):983‐6.

Jackson 2007

Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine 2007;25(17):3482‐4.

Krugman 1981

Krugman S, Holley HP, Davidson M, Simberkoff MS, Matsaniotis N. Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 microgram and 40 microgram doses. Journal of Medical Virology 1981;8(2):119‐21.

Lavanchy 2004

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004;11(2):97‐107.

Levy 1991

Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. American Journal of Perinatology 1991;8:227‐32.

Mahoney 1993

Mahoney FJ, Woodruff BA, Erben JJ, Coleman PJ, Reid EC, Schatz GC, et al. Effect of a hepatitis B vaccination program on the prevalence of hepatitis B virus infection. Journal of Infectious Diseases 1993;167(1):203‐7.

Mahoney 1999

Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. 3rd Edition. Philadelphia: W.B. Saunders Company, 1999:158‐82.

McMahon 1990

McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B‐related sequelae. Prospective study in 1400 hepatitis B surface antigen‐positive Alaska Native carriers. Archives of Internal Medicine 1990;150(5):1051‐4.

Ngui 1998

Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clinical Infectious Diseases 1998;27(1):100‐6.

Parkin 2001

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001;94(2):153‐6.

Reddy 1994

Reddy PA, Gupta I, Ganguly NK. Hepatitis‐B vaccination in pregnancy: safety and immunogenic response in mothers and antibody transfer to neonates. Asia‐Oceania Journal of Obstetrics and Gynaecology 1994;20(4):361‐5.

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Safary 2000

Safary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. Journal of Gastroenterology and Hepatology 2000;15(4):396‐401.

Schunemann 2009

Schunemann HJ. GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice [GRADE: Von der Evidenz zur Empfehlung. Beschreibung des Systems und Losungsbeitrag zur Ubertragbarkeit von Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2009;103(6):391‐400.

Shepard 2006

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Reviews 2006;28:112‐25.

Stevens 1985

Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive‐active immunization. JAMA 1985;253(12):1740‐5.

Wong 1984

Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink‐Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis‐B vaccine and hepatitis‐B immunoglobulin. Double‐blind randomised placebo controlled study. Lancet 1984;1(8383):921‐6.

Referencias de otras versiones publicadas de esta revisión

Sangkomkamhang 2011

Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007879.pub2]

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Gupta 2003

Study on immunogenicity and safety of HBV vaccine, comparisons of 2 doses HBV vaccine versus 3 doses in HBsAg negative pregnant women.

Li 2003

Study on 3 comparisons of HBIG versus lamivudine versus no treatment in HBsAg positive pregnant women for prevention of intrauterine infection of HBV.

Li 2004

Study on HBIG versus placebo in HBsAg positive pregnant women for prevention of intrauterine infection of HBV.

Patwardhan 2005

Study on HBV vaccine in both non‐pregnant and pregnant women for prevention of vertical transmission. Abstract only.

Wang 2008

Study on HBIG in HBsAg and HBeAg positive pregnant women for prevention of mother to infant HBV transmission.

Xu 2004

Study on lamivudine versus placebo in late pregnancy for mothers with high viremia, in addition to HBV vaccination plus HBIG for the infants for prevention of mother‐to‐child transmission of HBV.

Xu 2006

Study on HBIG versus placebo in HBeAg and HBsAg positive pregnant women for prevention of intrauterine infection of HBV.

Xu 2009

Study on lamivudine in highly viremic and late pregnancy for prevention of perinatal transmission of HBV infection.

Yu 2003

Study on HBIG in HBsAg positive pregnant women for prevention of intrauterine infection. This was an observational study.

Yuan 2006

Study on 3 doses of HBIG in seropositive for hepatitis B e antigen (HBeAg) pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.

Yue 1999

Study on HBIG in seropositive for hepatitis B surface (HBsAg) antigen pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.

Zhu 1997

Study on HBIG in HBV carriers pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV.

Zhu 2003

Study on 3 doses of HBIG in HBsAg carrier pregnant women versus no treatment for prevention of intrauterine transmission of HBV.

HBeAG: hepatitis B e antigen
HBIG: hepatitis B immunoglobulin
HBsAg: hepatitis B surface antigen
HBV: hepatitis B virus